Cargando…
Real-world evidence of switching P2Y12 receptor–inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry
BACKGROUND: Potent P2Y(12) inhibitors are recommended for up to 12 months after percutaneous coronary intervention (PCI) in patients diagnosed with acute coronary syndrome (ACS). However, the prescription pattern is diverse in real world practice, which includes various switching between antiplatele...
Autores principales: | Kang, Jeehoon, Han, Jung-Kyu, Yang, Han-Mo, Park, Kyung Woo, Kang, Hyun-Jae, Koo, Bon-Kwon, Choo, Eun Ho, Lee, Jong-Young, Park, Sang-Don, Lim, Young-Hyo, Kim, Hyung-Min, Heo, Ji-Hyun, Kim, Hyo-Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827633/ https://www.ncbi.nlm.nih.gov/pubmed/36624388 http://dx.doi.org/10.1186/s12872-022-03034-5 |
Ejemplares similares
-
Paraoxonase 1 Gene Polymorphism Does Not Affect Clopidogrel Response Variability but Is Associated with Clinical Outcome after PCI
por: Park, Kyung Woo, et al.
Publicado: (2013) -
Prasugrel-Based De-Escalation in Patients With Acute Coronary Syndrome According to Renal Function
por: Yun, Jun Pil, et al.
Publicado: (2023) -
Harmonizing Optimal Strategy for Treatment of coronary artery diseases – comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial
por: Lee, Joo Myung, et al.
Publicado: (2015) -
Association of Side-Branch Treatment and Patient Factors in Left Anterior Descending Artery True Bifurcation Lesions: Analysis from the GRAND-DES Pooled Registry
por: Oh, Gyu Chul, et al.
Publicado: (2020) -
Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)